A
Andrew Thomas
Researcher at Hoffmann-La Roche
Publications - 130
Citations - 5337
Andrew Thomas is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Alkyl & Alkoxy group. The author has an hindex of 23, co-authored 130 publications receiving 4919 citations.
Papers
More filters
Journal ArticleDOI
Modern Synthetic Methods for Copper‐Mediated C(aryl) ? O, C(aryl) ? N, and C(aryl) ? S Bond Formation
Steven V. Ley,Andrew Thomas +1 more
TL;DR: In this article, the authors highlight the recent developments in the copper-mediated (both stoichiometric and catalytic) reactions of aryl boronic acids as reaction partners in both O- and N-arylation.
Journal ArticleDOI
Organic synthesis provides opportunities to transform drug discovery
David C. Blakemore,Luis Castro,Ian Churcher,David C. Rees,Andrew Thomas,David Matthew Wilson,Anthony Wood +6 more
TL;DR: This Perspective highlights some of the most pressing challenges to be overcome from the industrial viewpoint — such as the development of reactions tolerating specific functionalities — and encourages stronger industry–academia relationships.
Journal ArticleDOI
Moderne Synthesemethoden: Kupfer-vermittelte C(Aryl)-O-, C(Aryl)-N- und C(Aryl)-S-Verknüpfungen
Steven V. Ley,Andrew Thomas +1 more
TL;DR: In this paper, the Palladium-vermittelten Arylierungsreaktionen are defined as Kupplungs-reaktionsen with einer grosen Bandbreite an Substraten.
Journal ArticleDOI
RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors
Theresa M. Ballard,Frédéric Knoflach,Eric Prinssen,Edilio Borroni,Jeffrey A. Vivian,Jeffrey A. Vivian,Jennifer Lee Basile,Rodolfo Gasser,Jean-Luc Moreau,Joseph G. Wettstein,Bernd Buettelmann,Henner Knust,Andrew Thomas,Gerhard Trube,Maria-Clemencia Hernandez +14 more
TL;DR: RO4938581 is a potent inverse agonist at the GABAA α5 receptor, with both binding and functional selectivity, enhancing hippocampal LTP, and further support the potential of GAB AA α5 receptors as a target for cognition-enhancing drugs.
Journal ArticleDOI
Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome.
Carmen Martínez-Cué,Paula Martínez,Noemí Rueda,Rebeca Vidal,Rebeca Vidal,Susana Truchuelo García,Verónica Vidal,Andrea Corrales,Juan A. Montero,Angel Pazos,Angel Pazos,Jesús Flórez,Rodolfo Gasser,Andrew Thomas,Michael Honer,Frédéric Knoflach,José Luis Trejo,Joseph G. Wettstein,Maria-Clemencia Hernandez +18 more
TL;DR: Reducing GABAergic inhibition with RO4938581 can reverse functional and neuromorphological deficits of TS mice by facilitating brain plasticity and support the potential therapeutic use of selective GABAA α5 NAMs to treat cognitive dysfunction in DS.